68 related articles for article (PubMed ID: 27926532)
1. Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution.
He JX; Wang M; Huan XJ; Chen CH; Song SS; Wang YQ; Liao XM; Tan C; He Q; Tong LJ; Wang YT; Li XH; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Gao ZW; Chen XY; Xiong B; Lu XL; Ding J; Yang CH; Miao ZH
Oncotarget; 2017 Jan; 8(3):4156-4168. PubMed ID: 27926532
[TBL] [Abstract][Full Text] [Related]
2. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.
Smith MA; Reynolds CP; Kang MH; Kolb EA; Gorlick R; Carol H; Lock RB; Keir ST; Maris JM; Billups CA; Lyalin D; Kurmasheva RT; Houghton PJ
Clin Cancer Res; 2015 Feb; 21(4):819-32. PubMed ID: 25500058
[TBL] [Abstract][Full Text] [Related]
3. Discovery and Proof of Concept of Potent Dual Polθ/PARP Inhibitors for Efficient Treatment of Homologous Recombination-Deficient Tumors.
Ma L; Chen W; Yang M; Ha S; Xiong S; Zhu J; Xiang H; Luo G
J Med Chem; 2024 Mar; 67(5):3606-3625. PubMed ID: 38375763
[TBL] [Abstract][Full Text] [Related]
4. A platform technology for ultra-long acting intratumoral therapy.
Henise J; Hangasky JA; Charych D; Carreras CW; Ashley GW; Santi DV
Sci Rep; 2024 Jun; 14(1):14000. PubMed ID: 38890412
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes.
Zhang F; Sun J; Zhang L; Li R; Wang Y; Geng H; Shen C; Li L; Chen L
Br J Cancer; 2024 May; ():. PubMed ID: 38806724
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitor combination therapy.
Dréan A; Lord CJ; Ashworth A
Crit Rev Oncol Hematol; 2016 Dec; 108():73-85. PubMed ID: 27931843
[TBL] [Abstract][Full Text] [Related]
7. PARP Inhibitors in Ovarian Cancer Treatment.
Spriggs DR; Longo DL
N Engl J Med; 2016 Dec; 375(22):2197-2198. PubMed ID: 27959768
[No Abstract] [Full Text] [Related]
8. A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy.
Kumar C; Rani N; Velan Lakshmi PT; Arunachalam A
Future Med Chem; 2017 Jan; 9(1):37-60. PubMed ID: 27995810
[TBL] [Abstract][Full Text] [Related]
9. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
George A; Kaye S; Banerjee S
Nat Rev Clin Oncol; 2017 May; 14(5):284-296. PubMed ID: 27958297
[TBL] [Abstract][Full Text] [Related]
10. PARP Inhibitors: Staying on Target?
Doig CL; Lavery GG
Cell Chem Biol; 2016 Dec; 23(12):1442-1443. PubMed ID: 28009975
[TBL] [Abstract][Full Text] [Related]
11. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
[TBL] [Abstract][Full Text] [Related]
12. Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials.
Nambiar DK; Mishra D; Singh RP
Oncol Res; 2023; 31(4):405-421. PubMed ID: 37415740
[TBL] [Abstract][Full Text] [Related]
13. Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance.
Wang LM; Wang P; Chen XM; Yang H; Song SS; Song Z; Jia L; Chen HD; Bao XB; Guo N; Huan XJ; Xi Y; Shen YY; Yang XY; Su Y; Sun YM; Gao YL; Chen Y; Ding J; Lang JY; Miao ZH; Zhang A; He JX
EMBO Mol Med; 2023 Mar; 15(3):e16235. PubMed ID: 36652375
[TBL] [Abstract][Full Text] [Related]
14. Absorption, distribution, metabolism, and excretion of [
Li XM; Zheng YD; Zhang YF; Huan XJ; Yang C; Liu ML; Shen XK; Yang CH; Diao XX
Cancer Chemother Pharmacol; 2022 Dec; 90(6):499-510. PubMed ID: 36283983
[TBL] [Abstract][Full Text] [Related]
15. Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion.
Guo N; Li MZ; Wang LM; Chen HD; Song SS; Miao ZH; He JX
Cancer Biol Ther; 2022 Dec; 23(1):69-82. PubMed ID: 35000525
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells.
Gao J; Wang Z; Fu J; A J; Ohno Y; Xu C
Exp Ther Med; 2021 Sep; 22(3):935. PubMed ID: 34335884
[TBL] [Abstract][Full Text] [Related]
17. An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19.
Ge Y; Tian T; Huang S; Wan F; Li J; Li S; Wang X; Yang H; Hong L; Wu N; Yuan E; Luo Y; Cheng L; Hu C; Lei Y; Shu H; Feng X; Jiang Z; Wu Y; Chi Y; Guo X; Cui L; Xiao L; Li Z; Yang C; Miao Z; Chen L; Li H; Zeng H; Zhao D; Zhu F; Shen X; Zeng J
Signal Transduct Target Ther; 2021 Apr; 6(1):165. PubMed ID: 33895786
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.
Badawy AA
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33063092
[TBL] [Abstract][Full Text] [Related]
19. Novel mutations in
Chen HD; Guo N; Song SS; Chen CH; Miao ZH; He JX
Am J Cancer Res; 2020; 10(9):2813-2831. PubMed ID: 33042619
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
